The data of national medical interview on hyperprolactinemia treatment in real clinical practice

Мельниченко, Г. А.; Афанасьевна, Мельниченко Галина; Dzeranova, Larisa; Константиновна, Дзеранова Лариса; Pigarova, Ekaterina; Александровна, Пигарова Екатерина; Vorotnikova, Svetlana; Юрьевна, Воротникова Светлана; Тарасова, Т. С.; Сергеевна, Тарасова Татьяна

doi:10.14341/omet2016214-19

Cited by 2 publications

(1 citation statement)

References 9 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Анкеты охватывали различные аспекты диагностики и лечения пролактином и ГПРЛ [4][5][6][7]. Всего 22-30% респондентов считали, что уровень пролактина (ПРЛ)<2000 мЕд/л исключает наличие пролактиномы.…”

Section: онлайн-опросы по гпрл врачей из разных странunclassified

Hyperprolactinemia in the postmenopause: versions and contraversions

Leshchenko

2021

Terapevticheskii arkhiv

View full text Add to dashboard Cite

The prevalence of hyperprolactinemia in postmenopausal women is unknown and has been estimated as infrequent by many studies. Prolactinomas found after menopause are usually macroadenomas and remain unrecognized for a long time due to atypical clinical signs or their absence. The growth potential of prolactinomas persists after menopause, most of them are invasive and accompanied by high prolactin levels. Treatment with dopamine agonists is usually long-term, the goals of which are to reduce tumor size, normalize prolactin levels and the negative effects of hyperprolactinemia. Treatment with cabergoline makes it possible to achieve remission of the disease in the first years after discontinuation, however, the proportion of relapses in postmenopausal women increases 5 years after discontinuation of the drug. Remission of prolactinomas is not evident in postmenopausal women. The modern management of patients with prolactinoma and/or hyperprolactinemia does not have clear positions in the postmenopausal period. Controversial issues remain: an ambiguous relationship between prolactin levels and breast cancer, there are no convincing conclusions on the improvement of bone mineral density and/or a decrease in the risk of fractures with normalization of prolactin levels, there are no data on metabolic parameters after the end of treatment with dopamine agonists, conflicting information about the relationship of prolactin levels and the severity of the manifold manifestations of the climacteric syndrome. The use of estrogen-progestin drugs in women with hyperprolactinemia/prolactinomas is also not well understood. Thus, the problem of hyperprolactinemia in the perimenopausal and postmenopausal period is underestimated and requires additional research, as well as the development of diagnostic and therapeutic strategies for potential benefits in terms of weight loss, improving insulin sensitivity, reducing the risk of fractures, maintaining sexuality and psycho-emotional well-being.

show abstract

Section: онлайн-опросы по гпрл врачей из разных странunclassified

Hyperprolactinemia in the postmenopause: versions and contraversions

Leshchenko

2021

Terapevticheskii arkhiv

View full text Add to dashboard Cite

show abstract

Hyperprolactinemic Hipogonadism: Prediction of Effectiveness Treatment and Management

Yermolenko,

Rozhkovska,

Andriyivskyy

2022

OMŽ

View full text Add to dashboard Cite

Hyperprolactinemia syndrome (HPRL) is one of the most common neuroendocrine diseases, leading to the development of hypogonadism in young women. The aim of the study was to study the effectiveness of treatment of menstrual and reproductive disorders caused by hyperprolactinemia, depending on the nature of the relationship of gonadotropic hormones. Materials and methods. 98 women of reproductive age were monitored, of which 78 — with functional HPRL and 20 healthy women. Clinical-anamnestic, enzyme-linked immunosorbent, instrumental (perimetry, computed tomography), functional, statistical research methods were used. The effectiveness of therapy for menstrual and reproductive disorders caused by HPRL, depending on the nature of the relationship of gonadotropic hormones (GH). Results. In patients of reproductive age with HPRL there are four types of GH secretion: the first — LH and FSH levels are reduced; the second — the level of LH is increased and FSH is reduced; third — the level of LH is reduced and FSH is increased; the fourth type — LH and FSH levels are both elevated. As a result of the treatment, ovarian function was restored in the first type of GH secretion in 83.6% of patients, in the second type — in 66.7% of patients, in the third — in 37.5%. In the group of women with HPRL and high levels of GH normalization of the menstrual cycle and restoration of reproductive function did not occur. Conclusions. Detection of four types of GH secretion in HPRL indicates the presence of different pathogenetic features of this pathology, which must be taken into account when prescribing personalized therapy to restore ovarian function and fertility, timely use of assisted reproductive technologies. Key words: hyperprolactinemia, hypogonadism, pathogenetic features, prognosis, therapy.

show abstract

The data of national medical interview on hyperprolactinemia treatment in real clinical practice

Cited by 2 publications

References 9 publications

Hyperprolactinemia in the postmenopause: versions and contraversions

Hyperprolactinemia in the postmenopause: versions and contraversions

Hyperprolactinemic Hipogonadism: Prediction of Effectiveness Treatment and Management

Contact Info

Product

Resources

About